Nothing Special   »   [go: up one dir, main page]

DE69027217D1 - TREATMENT OF INSULIN RESISTANT DIABETES - Google Patents

TREATMENT OF INSULIN RESISTANT DIABETES

Info

Publication number
DE69027217D1
DE69027217D1 DE69027217T DE69027217T DE69027217D1 DE 69027217 D1 DE69027217 D1 DE 69027217D1 DE 69027217 T DE69027217 T DE 69027217T DE 69027217 T DE69027217 T DE 69027217T DE 69027217 D1 DE69027217 D1 DE 69027217D1
Authority
DE
Germany
Prior art keywords
treatment
resistant diabetes
insulin resistant
insulin
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69027217T
Other languages
German (de)
Other versions
DE69027217T2 (en
Inventor
Angus Carstairs Maccuish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69027217D1 publication Critical patent/DE69027217D1/en
Publication of DE69027217T2 publication Critical patent/DE69027217T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Insulin-like growth factor (IGF) is used for treatment of type A insulin-resistant diabetes by reduction of glucose levels. The treatment is applicable to Mendenhall's Syndrome, Werner Syndrome, leprechaunism, lipoatrophic diabetes, and other lipoatrophies.
DE69027217T 1989-09-08 1990-09-10 TREATMENT OF INSULIN RESISTANT DIABETES Expired - Lifetime DE69027217T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898920381A GB8920381D0 (en) 1989-09-08 1989-09-08 Treatment of insulin-resistant diabetes
PCT/GB1990/001399 WO1991003253A1 (en) 1989-09-08 1990-09-10 Treatment of insulin-resistant diabetes

Publications (2)

Publication Number Publication Date
DE69027217D1 true DE69027217D1 (en) 1996-07-04
DE69027217T2 DE69027217T2 (en) 1996-10-02

Family

ID=10662782

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69027217T Expired - Lifetime DE69027217T2 (en) 1989-09-08 1990-09-10 TREATMENT OF INSULIN RESISTANT DIABETES

Country Status (11)

Country Link
US (1) US5674845A (en)
EP (1) EP0490955B1 (en)
JP (1) JP2513360B2 (en)
AT (1) ATE138578T1 (en)
AU (1) AU642665B2 (en)
CA (1) CA2066227A1 (en)
DE (1) DE69027217T2 (en)
DK (1) DK0490955T3 (en)
ES (1) ES2087162T3 (en)
GB (1) GB8920381D0 (en)
WO (1) WO1991003253A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9201573D0 (en) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab USE OF IGF-1
EP0602210A1 (en) * 1992-06-08 1994-06-22 Pharmacia AB (reg.number 556131-9608) Use of growth factor igf-i and/or igf-ii
JPH08500123A (en) * 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Method for modifying barrier properties of IGF-I sensitive cells, diagnostic method and screening method
SE9402370D0 (en) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
WO1998027813A1 (en) * 1996-12-24 1998-07-02 Amur Pharmaceuticals, Inc. Methods for treating insulin resistance and identifying patients at risk for the disease
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6627746B1 (en) 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
CZ300931B6 (en) * 1998-07-08 2009-09-16 Kirin-Amgen Inc. Preparation in powder form for mucosal administration
JP3141107B2 (en) * 1998-11-16 2001-03-05 工業技術院長 Human-derived bradion protein, DNA encoding the same, and uses thereof
US6902898B2 (en) * 1998-11-16 2005-06-07 National Institute Of Advanced Industrial Science And Technology Human derived bradeion proteins, DNA coding for the proteins, and uses thereof
WO2000040613A1 (en) 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
PT1165119E (en) 1999-04-08 2004-02-27 Genentech Inc COMPOSITION BASED ON POLIPEPTIDES WITH OPPOSED LOADS
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
DK1282437T3 (en) 2000-05-16 2008-06-30 Genentech Inc Treatment of cartilage disorders
NZ526672A (en) 2001-02-09 2006-10-27 Genentech Inc Process for forming crystalline human insulin-like growth factor-1
CA2702192A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
EP3609522A4 (en) * 2017-04-10 2021-05-05 Yoram Palti Methods and compounds for treating diabetes
CA3198225A1 (en) * 2020-10-13 2022-04-21 Betavive Ltd. Method and compounds for treating diabetes and associated metabolic diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU624596B2 (en) * 1987-12-16 1992-06-18 Genesis Systems Corporation Method and system for detection and treatment of premenstrual syndrome
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1

Also Published As

Publication number Publication date
EP0490955B1 (en) 1996-05-29
DE69027217T2 (en) 1996-10-02
GB8920381D0 (en) 1989-10-25
EP0490955A1 (en) 1992-06-24
JPH05504547A (en) 1993-07-15
CA2066227A1 (en) 1991-03-09
WO1991003253A1 (en) 1991-03-21
DK0490955T3 (en) 1996-06-24
AU6358090A (en) 1991-04-08
ATE138578T1 (en) 1996-06-15
AU642665B2 (en) 1993-10-28
ES2087162T3 (en) 1996-07-16
JP2513360B2 (en) 1996-07-03
US5674845A (en) 1997-10-07

Similar Documents

Publication Publication Date Title
DE69027217D1 (en) TREATMENT OF INSULIN RESISTANT DIABETES
SE8703625D0 (en) NEW MEDICAL USE
ATE50493T1 (en) MEDICATION CONTAINING IBUPROFEN.
DE3650499D1 (en) Use of "cartilage-inducing factor" (CIF) for the treatment of hemato- or lymphopoietic diseases
ATE163849T1 (en) MEDICINAL PRODUCTS CONTAINING R-ALPHA-LIPOIC ACID OR S-ALPHA-LIPOIC ACID AS THE ACTIVE INGREDIENTS
NO940180D0 (en) Use of IGF-I
ATE109979T1 (en) USE OF GUARANIDE DERIVATIVES FOR THE MANUFACTURE OF A DRUG WITH NPY ANTAGONIST ACTION.
IE873245L (en) Administering a deoxythymidine
DE69727811D1 (en) USE OF A GLUCOSE-CONTAINING SOLUTION IN PERITONEAL DIALYSIS WITH REDUCED FORMATION OF DECOMPOSITION PRODUCTS
NO175040C (en)
KR950703353A (en) Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus
BG60324B2 (en) New somatotropines
DE3781488D1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING 2 ', 3'-DIDEOXYCYTIDIN-2'-EN (2', 3'-DIDEOXY-2 ', 3'-DIDEHYDROCYTIDINE) FOR TREATING PATIENTS INFECTED WITH RETROVIRUS.
KR890004690A (en) Use of bezafibraid for the treatment of diabetes
IE822064L (en) Composition containing human insulin and c-peptide
DE3767308D1 (en) USE OF SULFONAMIDE DERIVATIVES FOR THE PRODUCTION OF AN ANTIVIRUS.
DE69600367D1 (en) Use of sulfasalazine and / or its active metabolites in the manufacture of a medicament for the treatment of venous insufficiency and venous ulcers
KR880000094A (en) Gastritis Treatment
KR880001630A (en) 5-fluorouracil derivatives and uses thereof
KR880013936A (en) Strong tricyclic imidazolone
JPS5665825A (en) Remedy for peptic ulcer
SE7706192L (en) ANTIMICROBIAL PASTE
KR880009017A (en) Isoxazole derivatives with antiviral activity and pharmaceuticals containing the same
SU637117A1 (en) Method of tuberculosis diagnosis
Rayfield Can strict glucose control prevent infections in diabetics?.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP